

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA OR CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. NEITHER THESE MATERIALS NOR THE INFORMATION CONTAINED HEREIN CONSTITUTE AN OFFER FOR SALE OF ANY SECURITY.



**Medartis Holding AG**  
Hochbergerstrasse 60E  
CH-4057 Basel

PRESS RELEASE

## **Medartis prices its IPO at CHF 48 per share and lists on the SIX Swiss Exchange**

Basel, Switzerland, 22 March 2018 – **Medartis Holding AG, a leading manufacturer and provider specialized in medical devices for internal surgical bone fixation, today announces that it has set the price for its initial public offering (IPO) at CHF 48 per share. The Medartis shares (SIX: MED) will be listed and trading will commence on the SIX Swiss Exchange tomorrow, 23 March 2018.**

- Medartis **prices its IPO at CHF 48** per offered share
- Offer price implies a **market capitalization of CHF 563 million** and a **free-float of 24.6%** (including the over-allotment shares)
- The offer was multiple times over-subscribed during the book-building period
- **IPO gross proceeds of CHF 123.9 million (CHF 142.6 million** including the over-allotment shares) will be used to finance the company's strategic growth initiatives
- Trading on SIX Swiss Exchange commences tomorrow

On behalf of Medartis, the Joint Global Coordinators placed 2,604,166 new registered shares as well as 390,625 over-allotment shares that will be issued simultaneously with the shares from the base offer. The offer was multiple times over-subscribed even at the upper end of the price range, given strong demand across Switzerland, Europe and the U.S. During the IPO, 114,688 shares were placed with a broad number of Medartis employees. The offer price was set at CHF 48, around the mid-point of the CHF 44-54 price range. This implies a market capitalization for Medartis of CHF 563 million based on the IPO, including the over-allotment shares.

Gross proceeds from the IPO will amount to CHF 123.9 million, or CHF 142.6 million including the over-allotment shares. The proceeds will be used to finance Medartis' international expansion efforts and further product developments, fund potential acquisitions and support other general corporate purposes.

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA OR CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. NEITHER THESE MATERIALS NOR THE INFORMATION CONTAINED HEREIN CONSTITUTE AN OFFER FOR SALE OF ANY SECURITY.

Following the IPO, Medartis founder and Chairman, Dr. h.c. Thomas Straumann, will remain the main shareholder with a stake of 47.9%, while Vice-Chairman Dominik Ellenrieder (via NexMed) will hold 7.9%, co-founder and CEO Willi Miesch 6.0%, and employees will hold 1.3% of the company. Endeavour Medtech Growth LP, Schroder & Co Bank AG and the bank Landolt & Cie SA will hold 4.96%, 4.5% and 3.3%, respectively. The free float of the company will amount to 24.6% and does not comprise the shares of existing shareholders, the shares resulting from the loan conversion as well as those of participating employees, which are all subject to a 12-month lock-up. All stakes are calculated including the over-allotment shares.

Underwriters for the IPO were Zürcher Kantonalbank and Bryan, Garnier & Co, who acted as Joint Global Coordinators and Joint Bookrunners, and Kepler Cheuvreux who acted as Co-Manager. Quarton International acted as financial advisor to the company.

Thomas Straumann, founder and Chairman of Medartis: “We are very happy with the response our IPO received from Swiss and international investors, and in the name of the Board of Directors and the management, I thank all our new investors for their trust in Medartis. We now look forward to continuing our path as a leading provider of innovative, high-quality, Swiss-made bone fixation system solutions. As a listed company, we will remain committed to constantly address our customers’ needs and will do our utmost to exploit our international growth opportunities and generate sustainable value for our shareholders.”

#### Key IPO data and indicative IPO timetable

<b>Key Data</b>	
<b>Listing</b>	SIX Swiss Exchange (International Reporting Standard)
<b>Ticker</b>	MED
<b>Swiss security number</b>	38 620 023
<b>ISIN</b>	CH0386200239
<b>Nominal value</b>	CHF 0.20 per share
<b>Final offer price</b>	CHF 48
<b>Base deal size</b>	2,604,166 new shares
<b>Over-allotment</b>	390,625 new shares
<b>Total number of registered shares post-IPO</b>	11,730,353 total outstanding shares
<b>Indicative IPO Schedule</b>	
Listing and first day of trading	23 March 2018
Book-entry of offered shares against payment of the offer price	27 March 2018
End of stabilization period (at the latest)	21 April 2018

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA OR CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. NEITHER THESE MATERIALS NOR THE INFORMATION CONTAINED HEREIN CONSTITUTE AN OFFER FOR SALE OF ANY SECURITY.

## Inquiries

Patrick Christ  
Medartis Holding AG  
Head Corporate Services  
Phone: +41 61 633 34 70  
[patrick.christ@medartis.com](mailto:patrick.christ@medartis.com)

Karin Rhomberg  
Lemongrass Communications AG  
Partner  
Phone: +41 44 202 52 65  
[karin.rhomberg@lemongrass.agency](mailto:karin.rhomberg@lemongrass.agency)

## About Medartis

Founded in 1997 and headquartered in Basel, Switzerland, Medartis is one of the world's leading manufacturers and providers of medical devices for surgical fixation of bone fractures and osteotomies for the craniofacial region as well as for upper and lower extremities. Medartis employs over 480 individuals across its 11 locations, and Medartis products are sold in 44 countries globally. For patients' welfare, Medartis is committed to providing surgeons and operating theatre personnel with the most innovative titanium implants and instruments as well as best in class services that represent advances in osteosynthesis. For more information, please visit [www.medartis.com](http://www.medartis.com).

### Disclaimer

*This announcement is not an offer to sell or a solicitation of any offer to buy any securities issued by Medartis Holding AG (the "Company") in any jurisdiction where such offer or sale would be unlawful, and the announcement and the information contained herein are not for distribution or release, directly or indirectly, in or into such jurisdictions.*

*This announcement and the information contained herein are not for distribution in or into the United States of America (including its territories and possessions, any state of the United States of America and the District of Columbia) (the "United States"). This document does not constitute, or form part of, an offer to sell, or a solicitation of an offer to purchase, any securities of the Company in the United States. The securities of the Company have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") and may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of the securities in the United States. Any securities sold in the United States will be sold only to "qualified institutional buyers" (as defined in Rule 144A under the Securities Act) in reliance on an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act.*

*This announcement is not an issuance or listing prospectus or a similar document in the sense of article 652a, article 752 and/or article 1156 of the Swiss Code of Obligations or articles 27 et seq. of the Listing Rules of the SIX Swiss Exchange and was not reviewed by any competent authority. Any offer of securities of the Company will be made solely by means of, and on the basis of, an offering memorandum that will contain detailed information about the Company and its management as well as risk factors and financial statements. Any person considering the purchase of any securities of the Company must inform itself independently based solely on such offering memorandum (including any supplement thereto).*

*In any member state of the European Economic Area ("EEA Member State"), this announcement is only addressed to and is only directed at persons in that EEA Member State who are "qualified investors" within the meaning of Article 2(1)(e) of the Prospectus Directive (Directive 2003/71/EC) ("Qualified Investors").*

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA OR CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. NEITHER THESE MATERIALS NOR THE INFORMATION CONTAINED HEREIN CONSTITUTE AN OFFER FOR SALE OF ANY SECURITY.

*In addition, in the United Kingdom, this announcement is being distributed only to, and is directed only at, Qualified Investors (i) who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended and Qualified Investors falling within Article 49(2)(a) to (d) of such Order, and (ii) to whom it may otherwise lawfully be communicated (all such persons together being referred to as "Relevant Persons"). The securities are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in only with, Relevant Persons. Any person who is not a Relevant Person should not act or rely on this document or any of its contents.*

*Zürcher Kantonalbank and Bryan Garnier & Co (each a "Manager", together the "Managers") and their affiliates are acting exclusively for the Company and no one else in connection with the offering. They will not regard any other person as their respective clients in relation to the offering and will not be responsible to anyone other than the Company and for providing the protections afforded to their respective clients, nor for providing advice in relation to the offering, the contents of this announcement or any transaction, arrangement or other matter referred to herein. In connection with the offering, the Managers and any of their affiliates, acting as investors for their own accounts, may subscribe for or purchase shares and in that capacity may retain, purchase, sell, offer to sell or otherwise deal for their own accounts in such shares and other securities of the Company or related investments in connection with the offering or otherwise. Accordingly, references in the Prospectus, to the shares being issued, offered, subscribed, acquired, placed or otherwise dealt in should be read as including any issue or offer to, or subscription, acquisition, placing or dealing by, such Managers and any of their affiliates acting as investors for their own accounts. The Managers do not intend to disclose the extent of any such investment or transactions otherwise than in accordance with any legal or regulatory obligations to do so. Zürcher Kantonalbank will not act as Manager in connection with any placements within the United States.*

*Matters discussed in this announcement may constitute forward-looking statements. Forward-looking statements are statements that are not historical facts and that can be identified by words such as "believe", "expect", "anticipate", "intends", "estimate", "will", "may", "continue", "should", and similar expressions. The forward-looking statements in this announcement are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that these assumptions were reasonable when made, these assumptions are inherently subject to significant known and unknown risks, uncertainties, contingencies and other important factors which are difficult or impossible to predict and are beyond its control. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The information, opinions and forward-looking statements contained in this announcement speak only as at its date, and are subject to change without notice.*